Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis
Journal of Drugs in Dermatology · 2026
DOI: 10.36849/jdd.9449 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Drugs in Dermatology, 2026. Verfasst von Brad R Woodie und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Interleukin-23, Tumor Necrosis Factor-alpha.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Woodie, B. R., Freking, J. A., Rivin, G. M., & Fleischer, A. B. (2026). Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.9449
Vancouver
Woodie BR, Freking JA, Rivin GM, Fleischer AB. Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis. Journal of Drugs in Dermatology. 2026. doi:10.36849/jdd.9449
BibTeX
@article{Woodie2026,
author = {Woodie, Brad R and Freking, Justin A and Rivin, Gabrielle M and Fleischer, Alan B},
title = {Decreased Nonmelanoma Skin Cancer Risk With Interleukin-17 and Interleukin-23 Inhibitors Versus TNF-α Inhibitors in Psoriasis},
journal = {Journal of Drugs in Dermatology},
year = {2026},
doi = {10.36849/jdd.9449}
}
EUVIMED